Project cooperation
Atopic Dermatitis Therapy Using MSC-Derived Extracellular Vesicles
Topical MSC-EV for AD: anti-inflammatory, barrier-rebuilding; preclinical efficacy > steroid; favorable safety.
- Planning
- Research
- Technical
- Financing
EXORPHIA, INC.
About
EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.
Through proprietary technologies, we have established high-activity EVs (Prime-EV), engineered EVs that can be flexibly loaded with antigens or drugs (Engineered EV), and an Advanced CMC platform that ensures reproducibility—all underpinned by a robust patent portfolio.
Our lead pipeline comprises three pillars:
(1) an IVF adjunct for infertility treatment (commercial launch in Japan planned for 2027–2028)
(2) an anti-inflammatory/anti-fibrotic therapy targeting ARDS, IPF, and atopic dermatitis (EXP01; aiming for a disease-modifying profile)
(3) an intranasal EV vaccine (EXP03; applicable from infectious-disease prevention to autoimmunity and oncology).
Through these programs, we will deliver safe, minimally invasive, and highly effective new treatments to clinical practice, and ultimately establish EVs as a versatile DDS platform to set a new standard for refractory diseases and preventive medicine.
Business Domain / 分野
Pharmaceuticals / 医薬品Healthcare / ヘルスケア
Business Type / 業種
R&D / 研究開発
Technologies / 技術
Pharmacological evaluation /薬効・薬理評価Drug delivery system(DDS) / ドラッグデリバリーシステム(DDS)Biomarkers /バイオマーカー
Disease Area / 疾患領域
Infectious diseases / 感染症Immunology / 免疫・炎症Dermatology and sensory system / 皮膚・感覚器
Modalities / モダリティ
Others /その他
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Major pharma etc. (Out-licensing purpose) / 大手ファーマ等（アウトライセンスを目的）
Researched disease area / マッチングご希望の疾患領域
Infectious diseases / 感染症Immunology / 免疫・炎症Dermatology and sensory system / 皮膚・感覚器
Researched Modality / マッチングご希望のモダリティ
Vaccine / ワクチンOthers / その他
Researched Technologies / マッチングご希望の技術
Biomarkers / バイオマーカーOthers /その他
Marketplace (5)
Project cooperation
Therapeutic for lung injury (ARDS, IPF) using MSC-derived Extracellular Vesicles（
MSC-EV for IPF/ARDS: dual anti-inflammatory/anti-fibrotic, disease-modifying; addresses efficacy-safety gap; FDA pre-IND cleared.
- Planning
- Research
- Technical
- Financing
Project cooperation
Engineered EV platform: intranasal multivalent vaccines for infectious diseases; DDS for oncology, autoimmune, and CNS indications.
- Planning
- Research
- Technical
- Financing
Project cooperation
IVF MSC-EV additive: trace-add to existing media (no workflow change) to raise good blastocysts; cut cycles/cost per birth; NEDO-funded.
- Planning
- Research
- Technical
- Financing
- Sales/Distribution
Partnership
EXORPHIA is seeking partners for EV therapeutics & delivery (EXP01, EXP03) and an IVF adjunct.
EXORPHIA is seeking partners for EV therapeutics & delivery—EXP01 (ARDS/IPF/AD), EXP03 vaccine—and an IVF adjunct.